Redox-responsive peptide folding enables intracellular self-assembly and controlled nucleic acid release.
Peptide self-assembly just got smarter. Researchers from Hunan University and Nanchang University have created a redox-responsive peptide that can fold, assemble, and release nucleic acids inside cells—on command. The trick is a well-placed disulfide bond that lets the peptide switch between a loose coil and a rigid β-hairpin, depending on the cell’s redox environment.
Mater Today Bio
by Dong H, Xie W, Huang W et al.
“Redox-responsive peptide folding enables intracellular self-assembly and controlled nucleic acid release. Dong H(1)(2), Xie W(2), Huang W(2), Fang Y(3), Wang M(2), Han H(2), Wu X(4), Zhang C(5), Deng J(6), Yuan D(2), Shi J(2). Author information: (1)School of Pharmacy, Institute of Biomedical Innovation, Jiangxi Medical College, Nanchang University, Nanchang, 330031, China. (2)Hunan Provincial Key Laboratory of Animal Models and Molecular Medicine, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, School of Biomedical Sciences, Hunan University, Changsha, Hunan, 410082, China. (3)HuanKui Academy, Jiangxi Medical College, Nanchang University, Nanchang, 330031, China. (4)Department of Cardiology, the Central Hospital of Xiangtan (The Affiliated Hospital of Hunan University), Xiangtan, Hunan, 411100, China. (5)College of Biology, Hunan University, Changsha, Hunan, 410082, China. (6)Wenzhou Institute, University of Chinese Academy Sciences, Wenzhou, Zhejiang, 325000, China. Intracellular peptide self-assembly provides a powerful strategy for spatiotemporal control of biomolecular interactions, yet most existing systems rely on irreversible triggers, limiting dynamic regulation. Herein, we report a redox-responsive amphiphilic peptide with a strategically positioned intramolecular disulfide bond, enabling reversible switching between a disordered coil and a β-hairpin conformation. In oxidized state, the peptide efficiently complexes with nucleic acids and penetrates cells. Intracellular glutathione reduction cleaves the disulfide, inducing β-hairpin folding, which drives supramolecular self-assembly into nanofibrils and concomitantly releases nucleic acid cargo. This three-step, reduction-responsive, assembly and release (RAR) mechanism achieves efficient, spatiotemporally controlled intracellular delivery. Structural, biophysical, and imaging analyses confirm the redox-triggered conformational transition, intracellular assembly, and cargo dissociation. This reversible and programmable platform establishes a generalizable design principle for stimulus-responsive biomaterials and nucleic acid therapeutics. © 2026 The Authors. PMCID: PMC13091059 Conflict of interest statement: The authors declare no competing financial interests.”
Here’s how it works:
The peptide stays in a disordered coil state outside the cell, holding onto nucleic acids.
Once inside, the high glutathione levels in the cytoplasm reduce the disulfide bond.
This reduction triggers the peptide to fold into a β-hairpin, which self-assembles into nanofibrils.
As the nanofibrils form, they push out the nucleic acid cargo for targeted delivery.
Key takeaway: This is a fully reversible, programmable system for precise control over when and where nucleic acids get released. No more relying on one-way triggers or hoping for passive release. Peptide folding and assembly can now be dialed up or down based on the cell’s chemistry.
The team validated every step with structural, biophysical, and imaging analyses. They saw direct evidence of redox-triggered folding, nanofibril formation inside cells, and successful cargo release. This three-step mechanism—reduction, assembly, release—adds a new layer of sophistication to the peptide research index and opens the door for more stimulus-responsive biomaterials.
Want to design your own redox-sensitive systems or explore programmable peptide assemblies? This research is a solid blueprint. The field of peptide-controlled delivery just leveled up.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.